Hims & Hers Health (NYSE:HIMS) Given New $13.25 Price Target at Citigroup

Hims & Hers Health (NYSE:HIMS) had its price objective dropped by Citigroup from $16.50 to $13.25 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “sell” rating on the stock. Citigroup’s price target would suggest a potential downside of 14.59% from the stock’s previous close.

HIMS has been the topic of several other research reports. Zacks Research cut shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Deutsche Bank Aktiengesellschaft set a $31.00 price objective on Hims & Hers Health and gave the company a “hold” rating in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $33.91.

Hims & Hers Health Price Performance

NYSE:HIMS traded up $0.00 during midday trading on Tuesday, hitting $15.51. The company had a trading volume of 41,878,764 shares, compared to its average volume of 27,557,242. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The stock’s fifty day moving average price is $28.21 and its 200-day moving average price is $40.02. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a market capitalization of $3.53 billion, a PE ratio of 28.76, a P/E/G ratio of 2.92 and a beta of 2.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.Hims & Hers Health’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period last year, the firm posted $0.11 EPS. As a group, research analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its Board of Directors has approved a stock repurchase plan on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Insider Activity

In other news, CFO Oluyemi Okupe sold 23,090 shares of Hims & Hers Health stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $35.72, for a total transaction of $824,774.80. Following the transaction, the chief financial officer owned 94,333 shares in the company, valued at $3,369,574.76. The trade was a 19.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the sale, the insider directly owned 6,175 shares in the company, valued at approximately $226,684.25. This trade represents a 53.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 82,963 shares of company stock valued at $2,944,621 in the last 90 days. 17.71% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Hims & Hers Health by 502.2% in the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock worth $127,237,000 after acquiring an additional 2,128,587 shares during the period. Norges Bank acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $62,153,000. Clear Street LLC acquired a new position in Hims & Hers Health in the second quarter worth approximately $83,582,000. Finally, Clear Street Group Inc. purchased a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $87,372,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Q4 beat on profitability and continuing subscriber/revenue growth — Hims & Hers topped EPS expectations and reported ~28% YoY revenue growth, showing improving unit economics that support longer‑term profitability. Read More.
• Positive Sentiment: Full‑year 2026 revenue framework aims at growth and international expansion — management guided 2026 revenue to $2.7B–$2.9B and is accelerating global expansion (including the announced Eucalyptus acquisition) to broaden its addressable market. Those initiatives could support revenue upside if execution stays on track. Read More. Read More.
• Neutral Sentiment: Earnings call highlighted strategy and investments — management emphasized record growth, tech investments and specialty launches while discussing regulatory scrutiny; the long‑term strategy remains intact but near‑term execution risk is higher. Read More.
• Negative Sentiment: Soft Q1 2026 sales guidance missed Street expectations — the company guided Q1 revenue to $600M–$625M versus a consensus near ~$650M, which undercut near‑term growth visibility and is a primary reason shares moved lower. Read More.
• Negative Sentiment: SEC investigation disclosed related to copycat/compounded GLP‑1 products — new regulatory/legal scrutiny raises potential compliance costs, product restrictions or liability, increasing execution risk for HIMS’s high‑growth weight‑loss business. Read More.
• Negative Sentiment: Analyst sentiment turned more cautious — BTIG downgraded HIMS from Buy to Neutral after the report, amplifying downside pressure as institutional flows respond to weaker guidance and regulatory headlines. Read More.
• Negative Sentiment: Market commentary frames the move as regulatory‑led outlook damage — several outlets interpret the combination of softer guidance and regulatory risk as the main driver of the selloff. Read More.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.